SignatureFD
PVLA icon

SignatureFD’s Palvella Therapeutics PVLA Stock Holding History

SignatureFD’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.59K Buy
26
+5
+24% +$741 ﹤0.01% 3039
2026
Q2 		$3.21K Sell
21
-29
-58% -$3.52K ﹤0.01% 3008
2026
Q1 		$6.23K Sell
50
-4
-7% -$417 ﹤0.01% 2696
2025
Q4 		$5.65K Buy
+54
New +$4.61K ﹤0.01% 2647

Other funds holding PVLA

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Clio Asset Management
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Lisanti Capital Growth
Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

SignatureFD's PVLA Position: Q3 2026 in Review

SignatureFD increased its Palvella Therapeutics (PVLA) stake by 24% in Q3 2026, buying an estimated $741 and bringing the position to 26 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

SignatureFD first reported a position in PVLA in Q4 2025 and has held it in 4 quarters since. The position peaked at $6.23K in Q1 2026. 67 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • SignatureFD held 26 shares of Palvella Therapeutics worth $3.59K as of Q3 2026.
  • SignatureFD bought 5 Palvella Therapeutics shares in Q3 2026, an estimated $741.
  • Palvella Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3039 holding.
  • SignatureFD first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • SignatureFD's Palvella Therapeutics position peaked at $6.23K in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.